Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014
Executive Summary
Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light
The latest drug development news and highlights from our US FDA Performance Tracker.
AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.